Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Adverse events were consistent with valbenazine’s established safety profile
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
